Watch Live

Tweet TWEET

Sponsorships, Pricing of Public Offering, and Investor Meetings - Research Report on Lilly, Mallinckrodt, Integra, and NuVasive

  Sponsorships, Pricing of Public Offering, and Investor Meetings - Research
             Report on Lilly, Mallinckrodt, Integra, and NuVasive

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 11, 2013

NEW YORK, November 11, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Eli Lilly
& Co. (NYSE: LLY), Mallinckrodt plc (NYSE: MNK), Integra Lifesciences Holdings
Corp. (NASDAQ: IART), Allscripts Healthcare Solutions Inc. (NASDAQ: MDRX), and
NuVasive, Inc. (NASDAQ: NUVA). Today's readers may access these reports free
of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Eli Lilly & Co. Research Report

On November 1, 2013, Lilly Diabetes, part of Eli Lilly & Co. (Lilly), and
Medtronic, Inc. (Medtronic) announced that they have teamed up to serve as
first ever national presenting sponsors of this season's JDRF Walk to Cure
Diabetes. According to Lilly, as national presenting sponsors, Lilly Diabetes
and Medtronic will host educational booths at select local events and will
work with their employees to form Walk teams at each location. The Companies
expect the sponsorship to help JDRF fund more than half a million dollars for
type 1 diabetes (T1D) research. Mike Mason, Vice President, U.S., Lilly
Diabetes, said, "Sponsoring the JDRF Walk to Cure Diabetes is an important
milestone in Lilly's partnership with Medtronic and means a lot to our
employees. Every day we strive to support people living with diabetes in their
journeys with the disease. Sponsoring the JDRF Walk to Cure Diabetes will
provide support the day of the walk and for years to come by helping JDRF
further its important work in diabetes research and advocacy." The Companies
expect 2014 Walks to begin around the U.S. on January 25, 2013. The Full
Research Report on Eli Lilly & Co. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

[http://www.analystscorner.com/r/full_research_report/977d_LLY]

--

Mallinckrodt plc Research Report

On November 6, 2013, Mallinckrodt plc (Mallinckrodt), along with
Pharmachemical Ireland, announced that as part of 2013 Science Week, the
Company has extended an invitation to schools to win scientific equipment by
participating in a poster competition. The theme of the competition is "What
Does Chemistry Mean in My Everyday Life?" and it is open to first-year
students in secondary schools in Dublin 15/County Meath area, with the first
place prize being €2500 worth of scientific equipment; second- and third-place
winners will receive equipment valued at €1000 and €500, respectively. The
last date to submit the entries is December 20, 2013. Mallinckrodt further
reported that the posters will be judged on the basis of design, content and
presentation. The Full Research Report on Mallinckrodt plc - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

[http://www.analystscorner.com/r/full_research_report/24f6_MNK]

--

Integra Lifesciences Holdings Corp. Research Report

On November 6, 2013, Integra LifeSciences Holdings Corporation (Integra)
announced that the Company has priced its previously announced underwritten
public offering of 3.5 million shares of its common stock at $40.00 per share.
Further, Integra has also granted the underwriters a 30-day option to purchase
an additional 525,000 shares of common stock. Integra informed that it intends
to use the net proceeds from the offering, including any net proceeds received
from an exercise of the underwriters' option to purchase additional shares,
for general corporate purposes which may include reducing outstanding
borrowings under Integra's senior credit facility and paying a portion of the
purchase price for the proposed acquisition by Integra Lifesciences
Corporation, the Company's wholly-owned subsidiary, of Cofluent Surgical,
Inc., including its DuraSeal product line. The Company expects the offering to
close on November 13, 2013, subject to customary closing conditions. The Full
Research Report on Integra Lifesciences Holdings Corp. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

[http://www.analystscorner.com/r/full_research_report/c0a4_IART]

--

Allscripts Healthcare Solutions Inc. Research Report

On November 1, 2013, Allscripts Healthcare Solutions Inc. (Allscripts)
announced that HealthCare Partners, LLC (HealthCare Partners) will expand its
nationwide partnership with the Company by further deploying the Allscripts
Enterprise Electronic Health Record (EHR) across its California medical group
sites and selecting the FollowMyHealth patient portal and the dbMotion
population health management solution. According to the Company, Allscripts
Enterprise is a robust solution for large, multi-specialty practices with some
of the most advanced features on the market. Further, Allscripts informed that
FollowMyHealth is a patient engagement solution that combines the value of a
personal health record, online patient portal, and the connectivity and
sharing of data that comes within a community of health. Paul M. Black, CEO of
Allscripts, said, "The combination of our Open Electronic Health Record,
patient engagement portal and community interoperability solutions will
empowerHealthCare Partnersto continue as a leader in this evolving
healthcare environment and better manage population health for the communities
it serves." The Full Research Report on Allscripts Healthcare Solutions Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/1787_MDRX]

--

NuVasive, Inc. Research Report

On November 4, 2013, NuVasive, Inc. (NuVasive) announced that it will host a
meeting for investors and analysts at NuVasive East office, 117 West Century
Road, Paramus, New Jersey, 07652, on November 14, 2013, from 8:30 a.m. ET to
11:00 a.m. ET. The Company reported that several senior members of the
executive team will come together to provide an in-depth progress report on
the top drivers of NuVasive's strategy for sustained growth with increasing
profitability. The Full Research Report on NuVasive, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

[http://www.analystscorner.com/r/full_research_report/c66c_NUVA]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.